| scholarly article | Q13442814 |
| P2093 | author name string | Dudley MN | |
| Zinner SH | |||
| Medeiros AA | |||
| Gilbert DH | |||
| Pivarnik P | |||
| Strayer AH | |||
| P2860 | cites work | Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate | Q35343060 |
| Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam | Q35360429 | ||
| Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes | Q35575783 | ||
| Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli | Q35650267 | ||
| Continuous infusion of beta-lactam antibiotics | Q35656806 | ||
| Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection | Q35818681 | ||
| Influence of beta-lactamase inhibitors on the potency of their companion drug with organisms possessing class I enzymes | Q36754084 | ||
| Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections | Q36758337 | ||
| Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors | Q39817435 | ||
| Kinetic interactions of tazobactam with beta-lactamases from all major structural classes | Q39865634 | ||
| Meeting the challenges of beta-lactamases | Q40884630 | ||
| Determinants of the activity of beta-lactamase inhibitor combinations | Q40884640 | ||
| The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria | Q44039660 | ||
| Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates. | Q54335837 | ||
| Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase. | Q54401131 | ||
| In-vitro bacterial killing kinetics of ticarcillin/clavulanic acid. | Q54411156 | ||
| Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease | Q67485735 | ||
| In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases | Q68459304 | ||
| Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography | Q69360876 | ||
| Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads | Q70148102 | ||
| Dose Dependence of Piperacillin Pharmacokinetics | Q72758425 | ||
| Therapy of soft tissue infections with piperacillin/tazobactam | Q72956634 | ||
| Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections | Q72956661 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacodynamics | Q725307 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 2351-2356 | |
| P577 | publication date | 1994-10-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection | |
| P478 | volume | 38 |
| Q34680546 | Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species |
| Q36730017 | Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations. |
| Q35128789 | Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions |
| Q39844968 | Expression of the AsbA1, OXA-12, and AsbM1 beta-lactamases in Aeromonas jandaei AER 14 is coordinated by a two-component regulon |
| Q33559047 | Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. |
| Q35134525 | Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. |
| Q34320027 | In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. |
| Q37625193 | Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation |
| Q40288977 | Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases |
| Q40325943 | Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases |
| Q38664871 | Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. |
| Q34462071 | Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy |
| Q43085417 | Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model |
| Q39001350 | Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam |
| Q42109987 | Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane |
| Q36439015 | Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children |
| Q33798377 | Population pharmacokinetic analysis of piperacillin in burn patients |
| Q41139120 | Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients |
| Q36158212 | Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations? |
| Q34216623 | Pulmonary penetration of piperacillin and tazobactam in critically ill patients. |
| Q39783646 | Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions |
| Q40389902 | The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection |
| Q26796425 | The β-Lactams Strike Back: Ceftazidime-Avibactam |
| Q39120027 | What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles |
Search more.